Evidence map›Paper›PMID 40836178›Full record

Observational studyInternal and emergency medicine2025

Hyperamylasemia in COVID-19 patients: pancreatic involvement or secondary epiphenomenon?

Marcello Candelli, Roberta Calce, Giulia Pignataro, Simona Racco, Mariella Fuorlo, Fabiana Barone, Andrea Piccioni, Giuseppe Merra, Veronica Ojetti, Antonio Gasbarrini and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Internal and emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcello CandelliEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy. marcello.candelli@policlinicogemelli.it.ORCID 0000-0001-8443-7880
Roberta CalceMedical, Abdominal Surgery and Endocrine-Metabolic Science Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.
Giulia PignataroEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy. giulia.pignataro@policlinicogemelli.it.
Simona RaccoEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.
Mariella FuorloEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.
Fabiana Barone
Andrea PiccioniEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.
Giuseppe MerraBiomedicine and Prevention Department, Section of Clinical Nutrition and Nutrigenomics, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma Tor Vergata, 00133, Rome, Italy.
Veronica OjettiDepartment of Internal Medicine, UniCamillus International Medical University of Rome, 00131, Rome, Italy.
Antonio GasbarriniMedical, Abdominal Surgery and Endocrine-Metabolic Science Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.
Francesco FranceschiEmergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, 00168, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated serum amylase has been frequently observed in COVID-19 patients, but whether hyperamylasemia results from a direct or indirect pancreatic effect or other mechanisms remains debated. Our study aimed to investigate the association between hyperamylasemia, pancreatitis, and COVID-19 severity. We retrospectively analyzed 1858 patients who visited the emergency department of Fondazione Policlinico Gemelli-IRCCS in Rome during the first two years of the pandemic. All had a confirmed COVID-19 diagnosis and underwent serum amylase evaluation. Clinical and laboratory data, including oxygen therapy requirements, intensive care unit (ICU) admission, and mortality, were extracted from electronic medical records. Univariate analysis revealed a correlation between hyperamylasemia and blood urea nitrogen, ICU admission, multiple comorbidities, and D-dimer levels. Multivariable logistic regression, adjusted for age, sex, comorbidities, and blood urea nitrogen, confirmed that ICU admission-but not in-hospital mortality-was independently associated with hyperamylasemia. Acute pancreatitis was diagnosed in only four patients. Elevated serum amylase levels appear more related to disease severity than direct pancreatic involvement. Emergency physicians should recognize that hyperamylasemia detected upon emergency department admission in COVID-19 patients may indicate an increased risk of ICU admission rather than acute pancreatitis, warranting closer evaluation and management.

Indexed as

AmylasesCOVID-19HyperamylasemiaPancreatitisAgedAged, 80 and overEmergency Service, HospitalFemaleHospital MortalityHumansIntensive Care UnitsMaleMiddle AgedOxygen Inhalation TherapyRetrospective StudiesSeverity of Illness IndexAmylasesCOVID-19HyperamylasemiaICUPancreasSARS-CoV-2Severity

Identifiers

PMID40836178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.